Literature DB >> 15026260

Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion.

Elizabeth Knyihár-Csillik1, Zoltán Chadaide, Etsuo Okuno, Beata Krisztin-Péva, József Toldi, Csaba Varga, Andor Molnár, Bert Csillik, László Vécsei.   

Abstract

Electrical stimulation of the trigeminal ganglion has been widely used as a model of nociception, characterizing migraine. This treatment is known to evoke release of neuropeptides and neurotransmitters from nerve fibers of the dura mater. On the basis of immunocytochemical investigations, we found that under normal conditions, surface membranes of Schwann cells surrounding nerve fibers in the supratentorial dura mater display kynurenine aminotransferase-immunoreaction (KAT-IR); also KAT-IR are the granules of mast cells and the cytoplasms of macrophages (histiocytes). In consequence of stimulation of the trigeminal ganglion, Schwann cells in the dura mater became conspicuously swollen while their KAT-IR decreased considerably; also KAT-IR of mast cells and macrophages decreased significantly. At the same time, nitric oxide synthase (NOS)-IR of nerve fibers in the dura mater increased, suggesting release of nitric oxide (NO), this is known to be involved in NMDA receptor activation leading to vasodilation followed by neurogenic inflammation. Because kynurenic acid (KYNA) is an antagonist of NMDA receptors, we hypothesize that KYNA and its synthesizing enzyme, KAT, may play a role in the prevention of migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026260     DOI: 10.1016/j.expneurol.2003.12.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

Review 1.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 3.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 4.  Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Authors:  Martina Curto; Luana Lionetto; Francesco Fazio; Dimos-Dimitrios Mitsikostas; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2015-02-24       Impact factor: 3.397

5.  Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.

Authors:  Annamária Fejes; Arpád Párdutz; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 6.  Kynurenines, neurodegeneration and Alzheimer's disease.

Authors:  Zsigmond Tamas Kincses; József Toldi; László Vécsei
Journal:  J Cell Mol Med       Date:  2010-07-12       Impact factor: 5.310

7.  Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.

Authors:  Levente Knapp; Bence Szita; Kitti Kocsis; László Vécsei; József Toldi
Journal:  Drug Des Devel Ther       Date:  2016-12-20       Impact factor: 4.162

8.  Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Authors:  Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei
Journal:  J Headache Pain       Date:  2021-06-25       Impact factor: 7.277

9.  Altered kynurenine pathway metabolites in serum of chronic migraine patients.

Authors:  Martina Curto; Luana Lionetto; Andrea Negro; Matilde Capi; Francesco Fazio; Maria Adele Giamberardino; Maurizio Simmaco; Ferdinando Nicoletti; Paolo Martelletti
Journal:  J Headache Pain       Date:  2016-04-29       Impact factor: 7.277

10.  KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion.

Authors:  M Lukács; K Warfvinge; L S Kruse; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2016-07-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.